A A Melcher
Overview
Explore the profile of A A Melcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melake M, Smith H, Mansfield D, Davies E, Dillon M, Wilkins A, et al.
Oncoimmunology
. 2022 May;
11(1):2066050.
PMID: 35558159
Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates....
2.
Harrington K, Bhide S, Forster M, Good J, Gunn L, Kong A, et al.
Clin Oncol (R Coll Radiol)
. 2020 Jun;
32(8):490-492.
PMID: 32513517
No abstract available.
3.
Close H, Stead L, Nsengimana J, Reilly K, Droop A, Wurdak H, et al.
Clin Exp Immunol
. 2019 Dec;
200(1):33-44.
PMID: 31784984
Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed as weakly immunogenic, GBM responds poorly to current immunotherapies. To understand this problem more clearly we used...
4.
Mansfield D, Kyula J, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan A, et al.
Gene Ther
. 2016 Jan;
23(4):357-68.
PMID: 26814609
Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase...
5.
Parrish C, SCOTT G, Migneco G, Scott K, Steele L, Ilett E, et al.
Leukemia
. 2015 Mar;
29(9):1799-810.
PMID: 25814029
The naturally occurring oncolytic virus (OV), reovirus, replicates in cancer cells causing direct cytotoxicity, and can activate innate and adaptive immune responses to facilitate tumour clearance. Reovirus is safe, well...
6.
El-Sherbiny Y, Holmes T, Wetherill L, Black E, Wilson E, Phillips S, et al.
Clin Exp Immunol
. 2014 Dec;
180(1):98-107.
PMID: 25469725
Human natural killer (NK) cells play an important role in anti-viral immunity. However, studying their activation kinetics during infection is highly problematic. A clinical trial of a therapeutic virus provided...
7.
Dave R, Jebar A, Jennings V, Adair R, West E, Errington-Mais F, et al.
Surgeon
. 2014 Feb;
12(4):210-20.
PMID: 24502935
Background: Despite mankind's many achievements, we are yet to find a cure for cancer. We are now approaching a new era which recognises the promise of harnessing the immune system...
8.
Jennings V, Ilett E, Scott K, West E, Vile R, Pandha H, et al.
Int J Cancer
. 2013 Aug;
134(5):1091-101.
PMID: 23982804
Reovirus is an oncolytic virus (OV), which acts by both direct tumor cell killing and priming of antitumor immunity. A major obstacle for effective oncolytic virotherapy is effective delivery of...
9.
Kyula J, Khan A, Mansfield D, Karapanagiotou E, Mclaughlin M, Roulstone V, et al.
Oncogene
. 2013 Apr;
33(13):1700-12.
PMID: 23624923
Melanoma is an aggressive skin cancer that carries an extremely poor prognosis when local invasion, nodal spread or systemic metastasis has occurred. Recent advances in melanoma biology have revealed that...
10.
Mansfield D, Pencavel T, Kyula J, Zaidi S, Roulstone V, Thway K, et al.
Oral Oncol
. 2012 Aug;
49(2):108-18.
PMID: 22925693
Objective: Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with radiotherapy may reveal exploitable synergistic relationships. Materials And Methods: In...